# Cabazitaxel in Relapsed and Metastatic NSCLC

> **NCT01852578** · PHASE2 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 46 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Cabazitaxel

## Key facts

- **NCT ID:** NCT01852578
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01852578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01852578, "Cabazitaxel in Relapsed and Metastatic NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01852578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*